Ardena, a specialist pharmaceutical contract development and manufacturing organization (CDMO), will be expanding its capacity for purification and fractionation of GMP manufacturing at its site in Södertälje, Sweden. The expansion will satisfy long-term demand expected from Novavax for production of the company’s COVID-19 vaccine, among others.   The expansion comes following the grant of conditional marketing authorization by the European Commission for Novavax’s COVID-19 vaccine, Nuvaxovid.  ...